Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice via Modulation of NFATc1

Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice via Modulation of NFATc1

Osteoporosis is a metabolic bone disease characterized by insufficient osteoblastic function and/or excessive osteoclastic activity. One promising strategy for treating osteoporosis is inhibiting excessive osteoclast resorbing activity. Previous studies have revealed that anemonin (ANE), isolated fr...

Full description

Bibliographic Details
Main Authors: Huanhuan Hou, Qisheng Peng, Shaoming Wang, Yuxin Zhang, Jinjin Cao, Yuming Deng, Yingjian Wang, Wan-chun Sun, Hong-bing Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Pharmacology
Subjects:
osteoclasts
anemonin
NFATc1
Blimp1
NF-κB
ERK1/2
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01696/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.01696/full

Similar Items